Cargando…
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections
SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for nontuberculous mycobacterial pulmonary disease (NTM-PD) and pulmonary tuberculosis. SPR719 has demonstrated activity against clinically relevant mycobacteria in vitro and in mu...
Autores principales: | Talley, Angela K., Thurston, Archie, Moore, Grayson, Gupta, Vipul K., Satterfield, Myriah, Manyak, Erika, Stokes, Suzanne, Dane, Aaron, Melnick, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525492/ https://www.ncbi.nlm.nih.gov/pubmed/34491803 http://dx.doi.org/10.1128/AAC.01208-21 |
Ejemplares similares
-
1288. Phase 1 First-in-Human Single- and Multiple-Ascending Dose Trial Demonstrates Pharmacokinetics (PK) and Tolerability of SPR720, an Oral DNA GyrB Inhibitor for Mycobacterial Infections
por: Talley, Angela, et al.
Publicado: (2020) -
1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020) -
A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function
por: Schoeffler, Allyn J., et al.
Publicado: (2010) -
Identification of the likely translational start of Mycobacterium tuberculosis GyrB
por: Karkare, Shantanu, et al.
Publicado: (2013) -
New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations
por: Malik, Seidu, et al.
Publicado: (2012)